Clinical trials · Tennessee
Advanced or Metastatic Solid Tumors clinical trials in Tennessee
We’re tracking 389 recruiting advanced or metastatic solid tumors studies with a site in Tennessee — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT07027514RecruitingPhase 1
Combination treatment for advanced lung cancer
This study tests a new drug called tolododekin alfa combined with an approved immunotherapy drug for people with advanced non-small cell lung cancer. The goal is to see if this combination is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Nashville, TennesseeAges 18 years+ - NCT06966024RecruitingPhase 1
Study of DCC-2812 for advanced genitourinary cancers
This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.
Nashville, TennesseeAges 18 years+ - NCT06950034RecruitingPhase 1
Testing STX-0712 for advanced CMML or AML
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
Nashville, TennesseeAges 18 years+ - NCT06926920RecruitingPhase 1/Phase 2
Testing a new dose schedule of sacituzumab govitecan for advanced TNBC
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
Nashville, TennesseeAges 18 years+ - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Chattanooga, TennesseeAges 18 years+ - NCT06904391Recruiting
Helping advanced practice providers start cancer research at their clinics
This study tests whether extra training and mentorship help nurse practitioners and physician assistants lead more cancer research studies at their own clinics. If you are an APP who wants to grow research at your practice, this program could give you the support you need.
Memphis, TennesseeAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Nashville, TennesseeAges 18 years+ - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Nashville, TennesseeAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Germantown, TennesseeAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Nashville, TennesseeAges 18 years+ - NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Nashville, TennesseeAges 18 years+ - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
Nashville, TennesseeAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Knoxville, TennesseeAges 18 years+ - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Nashville, TennesseeAges 18 years+ - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Chattanooga, TennesseeAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Nashville, TennesseeAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Collierville, TennesseeAges 18 years+ - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Memphis, TennesseeAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
Nashville, TennesseeAges 18 years+ - NCT06526195Recruiting
A study of CardioMEMS and HeartMate 3 for advanced heart failure
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
Memphis, TennesseeAges 18 years+ - NCT06504589Recruiting
Study for CF treatments for people without modulators
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
Nashville, TennesseeAges 12 years+ - NCT06467357RecruitingPhase 3
New drug combo for advanced bile duct cancer with HER2
This study tests a new combination of drugs for advanced bile duct cancer that has not been treated yet and shows a protein called HER2. It compares the new combination to the standard treatment to see if it works better or has fewer side effects.
Nashville, TennesseeAges 18–99 - NCT06433011Recruiting
New clot-busting method for pulmonary embolism
This study tests a new way of delivering a clot-dissolving medicine for people with a serious but not immediately life-threatening pulmonary embolism. The goal is to see if giving the medicine as small bursts directly into the clot can help the heart recover faster.
Nashville, TennesseeAges Any age
Advanced or Metastatic Solid Tumors trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Vanderbilt University Medical Center · 9 studies
- SCRI Oncology Partners · 5 studies
- Baptist Memorial Hospital and Cancer Center-Memphis · 2 studies
- Baptist Memorial Hospital and Cancer Center-Collierville
- ClinSearch, LLC
- Erlanger Health System
- Innovative Clinical Research
- Research Site
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced or Metastatic Solid Tumors trials in other states
Common questions
- Are there advanced or metastatic solid tumors clinical trials in Tennessee?
- Yes. We're currently tracking 389 recruiting advanced or metastatic solid tumors studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.